Cohort selection refers to the process of identifying and enrolling patients into clinical trials or treatment protocols based on specific biomarkers, tumor characteristics, and predicted treatment responsiveness. In precision medicine and oncology, cohort selection has become increasingly critical as therapeutic approaches become more targeted and patient populations more stratified. The goal is to match individual patients with treatments or trials most likely to yield clinical benefit, thereby improving outcomes and reducing unnecessary exposure to ineffective therapies.

Cohort selection bridges the gap between population-level clinical evidence and individual patient characteristics. Traditional clinical trial designs enrolled broad patient populations, but modern oncology recognizes that patients with apparently similar diagnoses may respond differently to identical treatments due to underlying molecular heterogeneity. Effective cohort selection requires integration of multiple data sources: histopathological findings, genomic sequencing results, biomarker expression levels, and patient clinical history.

The clinical significance of cohort selection extends beyond individual outcomes. By ensuring that patients enrolled in trials possess characteristics predictive of treatment response, trial designs become more statistically powerful, reducing required sample sizes and accelerating drug development timelines. This approach has become standard practice in precision oncology, where targeted therapies designed for specific mutations or biomarker profiles require careful patient matching to demonstrate efficacy ¹⁾

Modern cohort selection relies heavily on biomarker identification and validation. Biomarkers—measurable biological characteristics that predict treatment response—range from single-gene mutations to complex multi-gene signatures. In lung cancer, for example, patients with specific EGFR mutations demonstrate dramatically different responses to EGFR inhibitors compared to wild-type populations, necessitating molecular screening before treatment initiation.

Genomic profiling has become increasingly accessible and cost-effective, enabling broader biomarker-based stratification. Tumor sequencing identifies actionable mutations, copy number variations, and chromosomal rearrangements that inform treatment selection. Beyond DNA-level alterations, transcriptomic profiling reveals gene expression patterns that correlate with treatment response, while proteomic approaches measure protein levels that may indicate therapeutic sensitivity. Immunotherapy cohort selection increasingly incorporates tumor microenvironment characteristics, including immune infiltration patterns and checkpoint inhibitor expression levels ²⁾.

Artificial intelligence and machine learning have enhanced cohort selection capabilities by integrating diverse data modalities and identifying complex patterns predictive of treatment response. AI-based approaches can process high-dimensional biomarker data, clinical characteristics, and outcomes data to build predictive models that assign patients to optimal treatment pathways. These systems learn from historical patient outcomes to refine matching algorithms, improving predictive accuracy over time.

AI applications in cohort selection address several key challenges: handling missing or incomplete data, integrating data from multiple sources with different formats, identifying non-linear relationships between biomarkers and outcomes, and personalizing predictions to account for patient-specific factors beyond biomarkers alone ³⁾. Natural language processing extracts relevant clinical information from unstructured medical records, while ensemble methods combine multiple prediction models to improve robustness and generalization.

Cohort selection has become standard practice in contemporary oncology trials, particularly for targeted therapies and immunotherapies. Pharmaceutical companies increasingly employ cohort selection strategies to identify patient subpopulations most likely to respond to investigational drugs, improving trial success rates and regulatory approval likelihood.

Despite advances, cohort selection faces several limitations. Biomarker discovery remains incomplete for many cancer types, and identified biomarkers often show modest predictive power when applied across diverse patient populations. Tumor heterogeneity—both inter-tumoral and intra-tumoral—creates variability in biomarker expression that complicates selection criteria. Additionally, access to comprehensive genomic profiling and biomarker testing varies geographically and by healthcare system resources, potentially creating disparities in treatment opportunities ⁴⁾. Regulatory frameworks continue evolving to accommodate increasingly complex selection criteria, requiring clear validation of biomarker-treatment relationships through rigorously designed clinical trials.

• Biomarker-Driven Treatment Selection
• Transfer Learning for Sparse Clinical Populations
• Patient Similarity Analysis (N-of-1 Reasoning)